Influence of recombinant human interleukin (IL)‐7 on disease progression in mice infected with friend virus complex

Li Lu, Zhen Zhou, Bo Wu, Mang Xiao, Rong‐Nian ‐N Shen, Douglas E. Williams, Young‐Junc ‐J Kim, Byoung S. Kwon, Sandra Ruscetti, Hal E. Broxmeyer

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Recombinant human (rhu) IL-7 was evaluated for its influence on disease progression in mice infected with the polycythemia-inducing strain of the Friend virus complex (FVC). DBA/2 mice were injected i.v. with FVC, and then treated s.c. with rhuIL-7. IL-7 significantly prolonged survival time and decreased spleen focus-forming virus (SFFV) levels, expression of SFFV mRNA and SFFV protein production in FVC-infected mice. IL-7 did not appear to directly inactivate SFFV. Although both splenic weight and cellularity in FVC-infected mice treated with IL-7 were higher than those of normal mice, they were respectively 58% and 66% lower than those of the untreated FVC-infected mice. NK-cell activity was substantially lower in FVC-infected mice than in normal mice, while IL-7 restored NK-cell activity to normal levels. IL-6 and IFN-γ levels were markedly reduced in FVC-infected mice compared to normal mice, but treatment of FVC-infected mice with IL-7 restored these cytokine levels. While the actual mechanisms of these effects are not yet known, the results suggest the potential therapeutic efficacy of IL-7 for certain hematopoietic and viral disorders, possibly mediated through an action on accessory cells and cytokine production.

Original languageEnglish (US)
Pages (from-to)261-265
Number of pages5
JournalInternational Journal of Cancer
Volume52
Issue number2
DOIs
StatePublished - Sep 9 1992

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this